CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced its participation in two upcoming events in June:
•13th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on Saturday, June 20. At ICML, updated data from the ongoing Phase 1 trial of EZH2 inhibitor tazemetostat (EPZ-6438) in advanced B-cell non-Hodgkin lymphoma (NHL) or advanced solid tumors will be presented at 10:35 a.m. CEST / 4:35 a.m. ET.
Help employers find you! Check out all the jobs and post your resume.
